To determine the mechanism by which SYDC ameliorates atherosclerosis via the PI3K/Akt/mTORC1 signaling pathway, we tested the effects of LY294002 (PI3K inhibitor), TRICI (p-Akt inhibitor), and rapamycin (mTORC1 inhibitor) on ox-LDL-stimulated macrophages. The gene discussed is AKT1; the disease is atherosclerosis.